Skip to content

Study · Non-randomized trial · n = 34 · 1993

4 results

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors.

Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, Kelsen D

Cancer1 Jul 1993Cited by 174 (Europe PMC)

PMID8389666 (opens in a new tab)DOI10.1002/1097-0142(19930701)72:1<244::aid-cncr2820720143>3.0.co;2-q (opens in a new tab)PepBankPUB-08389666
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In advanced neuroendocrine tumors treated with octreotide, median survival was not reached at median follow-up of 29 months (range, 1-47 months).

    In plain wordsIn advanced neuroendocrine tumors treated with octreotide, median survival was not reached during follow-up.

    Peptide
    Octreotide
    Outcome
    Direction not reportedMedian survival
    Study

    n = 34

    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Median follow-up
    29 months
    advanced neuroendocrine tumors, 34 patients
    Follow-up range
    1 to 47 months
    advanced neuroendocrine tumors, 34 patients

    Source sentences

    Summary
    The median survival for this patient population from the start of octreotide therapy has not been reached, with a median follow-up of 29 months (range, 1-47 months).
    3 context sentences
    Summary · context
    Thirty-four patients with advanced neuroendocrine tumors were treated with octreotide as antineoplastic therapy.
    Summary · context
    This treatment was begun only after documentation of clear objective progression of disease.
    Summary · context
    A Phase II trial was performed at a tertiary comprehensive cancer center.
  2. 02HumanNon-randomized trialEfficacy outcome

    In advanced neuroendocrine tumors treated with octreotide, no major objective tumor regressions occurred.

    In plain wordsIn advanced neuroendocrine tumors treated with octreotide, no major tumor regressions occurred.

    Peptide
    Octreotide
    Outcome
    Not applicableMajor objective tumor regression
    Study

    n = 34

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No major objective tumor regressions were seen.
    3 context sentences
    Summary · context
    Thirty-four patients with advanced neuroendocrine tumors were treated with octreotide as antineoplastic therapy.
    Summary · context
    This treatment was begun only after documentation of clear objective progression of disease.
    Summary · context
    A Phase II trial was performed at a tertiary comprehensive cancer center.
  3. 03HumanNon-randomized trialEfficacy outcome

    In advanced neuroendocrine tumors, octreotide treatment accompanied CT-documented disease stabilization in 17 patients (50%), maintainable for a minimum of 2 months (median 5 months; range 0-27).

    In plain wordsIn advanced neuroendocrine tumors, 17 patients (50%) had disease stabilization during octreotide treatment.

    Peptide
    Octreotide
    Outcome
    Not applicableDisease stabilization
    Study

    n = 34

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Patients with disease stabilization
    17 patients
    octreotide, 50% of 34 patients
    Minimum duration of stabilization
    2 months
    octreotide
    Median duration of stabilization
    5 months
    octreotide
    Duration of stabilization range
    0 to 27 months
    octreotide

    Source sentences

    Summary
    Seventeen patients (50%) experienced a computed tomography-documented stabilization of disease that was maintainable for a minimum of 2 months (median, 5 months; range, 0-27 months).
    3 context sentences
    Summary · context
    Thirty-four patients with advanced neuroendocrine tumors were treated with octreotide as antineoplastic therapy.
    Summary · context
    This treatment was begun only after documentation of clear objective progression of disease.
    Summary · context
    A Phase II trial was performed at a tertiary comprehensive cancer center.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients receiving octreotide as first antineoplastic therapy, median survival was not reached at median follow-up of 29 months (range, 12-41 months).

    In plain wordsIn patients receiving octreotide as first cancer therapy, median survival was not reached during follow-up.

    Peptide
    Octreotide
    Outcome
    Direction not reportedMedian survival with first antineoplastic therapy
    Study

    n = 20

    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Median follow-up
    29 months
    octreotide as first antineoplastic therapy, 20 patients
    Follow-up range
    12 to 41 months
    octreotide as first antineoplastic therapy, 20 patients

    Source sentences

    Summary
    The median survival for these 20 patients has not been reached, with a median follow-up also of 29 months (range, 12-41 months).
    4 context sentences
    Summary · context
    Of the 34 patients, 20 patients received octreotide as their first antineoplastic therapy.
    Summary · context
    Thirty-four patients with advanced neuroendocrine tumors were treated with octreotide as antineoplastic therapy.
    Summary · context
    This treatment was begun only after documentation of clear objective progression of disease.
    Summary · context
    A Phase II trial was performed at a tertiary comprehensive cancer center.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.